Open AccessChoice of therapeutic tactics after failure of the first tumor necrosis factor-α inhibitor
Author(s) -
Н. В. Чичасова
Publication year - 2017
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2017-3-106-111
Subject(s) - golimumab , abatacept , rheumatoid arthritis , discontinuation , tocilizumab , medicine , tumor necrosis factor alpha , rituximab , tnf inhibitor , etanercept , adverse effect , tumor necrosis factor α , oncology , immunology , antibody